CRUSH!!MDS 

2015 Clinical Research Consortium American Society of Hematology Abstracts

Oral Presentations

1. 94 - Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium (Oral Presentation)
   Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Mikkael A. Sekeres, MD, MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Gail J Roboz, MD, Tapan Kadia, MD, Gautam Borthakur, MD1, Courtney DiNardo, MD, Darla Miller, Zeev Estrov, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD and Elias Jabbour
   
   
2. 609 - An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (Oral Presentation)
   Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD, MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD, MHS, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A van de Loosdrecht, MD, PhD, Richard F. Schlenk, MD, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, MD, Dolors Costa, Aristoteles Giagounidis, MD, PhD, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, Maria Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, Detlef Haase, MD, Ana Africa Martin, Claudia D Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, MSc, Brayan Merchan, MD, Claudia Mende, María Teresa Ardanaz, MD, Christina Ganster, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Nomdedeu Benet, Peter L. Greenberg, MD, Ulrich Germing, MD and Guillermo Sanz, MD, PhD
   
   
3. 907 - Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (Oral Presentation)
   Rafael Bejar, MD, PhD, Elli Papaemmanuil, PhD, Torsten Haferlach, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, MD, Ph.D., Mikkael A. Sekeres, MD, MS, Matthew J. Walter, MD, Timothy A. Graubert, MD, Mario Cazzola, MD, Luca Malcovati, MD, Seishi Ogawa, MD, Ph.D., Pierre Fenaux, MD, PhD, Eva Hellstrom-Lindberg, MD, PhD, Wolfgang Kern, MD, Jacqueline Boultwood, PhD, Andrea Pellagatti, PhD, David Bowen, MD, PhD, Sudhir Tauro, PhD, Michael J Groves, PhD, Paresh Vyas, MD, PhD, Lynn Quek, MD, Aziz Nazha, MD, Felicitas Thol, MD, Michael Heuser, M.D., Lee-Yung Shih, MD, Eric Padron, MD, David Sallman, M.D., Rami S. Komrokji, MD, Alan F. List, MD, Valeria Santini, MD, Michaela Fontenay, MD, PhD, Peter J Campbell, MD, PhD, Heinz Tüchler, Kristen Stevenson, MS, Donna S Neuberg, ScD, Peter Greenberg, MD and Benjamin L Ebert, MD, PhD
   
   
4. 909 - Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) (Oral Presentation)
   Rami S. Komrokji, MD, Amy E. DeZern, MD, MHS, Katrina Zell, MA, MS, Najla H. Al Ali, BDS, MSc, Christopher Estling, Cassie Zimmerman, MPH, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, PhD, Gail J Roboz, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD and Mikkael A. Sekeres, MD, MS
   
   
5. 911 - A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS) (Oral Presentation)
   Guillermo Garcia-Manero, MD, Jesus G. Berdeja, MD, Rami S. Komrokji, MD, James Essell, MD, Roger M. Lyons, MD, Michael Maris, MD, Amy E. DeZern, MD, MHS, Mikkael A. Sekeres, MD, MS and Gail J Roboz, MD

Poster Presentations

1. 1138 - North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia (Poster)
   Alexander B Pine, MD PhD, Eun-Ju Lee, MD, Mikkael A. Sekeres, MD, MS, David P. Steensma, MD, Thomas Prebet, MD, Amy E. DeZern, MD, MHS, Rami S. Komrokji, MD, Mark R Litzow, MD, Selina Luger, MD, Richard M. Stone, MD, Harry P. Erba, MD, PhD, Guillermo Garcia-Manero, MD, Alfred I Lee, MD, PhD, Nikolai A. Podoltsev, MD, PhD, Lisa Barbarotta, APRN-BC, Jeanne E. Hendrickson, MD, Steven D. Gore, MD and Amer M. Zeidan, MBBS, MHS
   
   
2. 1683 - Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) (Poster)
   Michael R. Savona, MD, Olatoyosi Odenike, MD, Philip C. Amrein, MD, David P. Steensma, MD, Wael A. Harb, MD, Amy E. DeZern, MD, MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganesian, PhD, Richa Dua, PharmD, Roya Nawabi, Mohammad Azab, MD and Guillermo Garcia-Manero, MD
   
   
3. 1696 - Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs) (Poster)
   Mikkael A. Sekeres, MD, MS, Katrina Zell, MA, MS, John Barnard, PhD, Amy E. DeZern, MD, MHS, David P. Steensma, MD, Cassie Zimmerman, MPH, Christopher Estling, MS, Wesley Hand, Gail J. Roboz, MD, Nicole Rizzo, Najla H. Al Ali, BDS, MSc, Alan F. List, MD, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, MD, PhD and Rami S. Komrokji, MD
   
   
4. 1697 - Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC) (Poster)
   Rami S. Komrokji, MD, Amy E. DeZern, MD, MHS, Katrina Zell, MA, MS, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Christopher Estling, Cassie Zimmerman, MPH, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, PhD, Gail J Roboz, MD, Hetty E. Carraway, MD, MBA, Jaroslaw P. Maciejewski, MD, PhD, Alan F. List, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD and Mikkael A. Sekeres, MD, MS
   
   
5. 1705 - Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities (Poster)
   David Sallman, M.D., Guillermo Garcia-Manero, MD, Elias Jabbour, Mikkael A. Sekeres, MD, MS, Amy E. DeZern, MD, MHS, David P. Steensma, MD, Gail J. Roboz, MD, John Barnard, PhD, Najla H. Al Ali, BDS, MSc, Cassie Zimmerman, MPH, Sherry Pierce, BSN, BA, Denise Batista, PhD, Jeffrey E Lancet, MD, Eric Padron, M.D., Jaroslaw P. Maciejewski, MD, Ph.D., Alan F. List, MD, Hagop M. Kantarjian, MD and Rami S. Komrokji, MD
   
   
6. 2877 - Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS) (Poster)
   Guillermo Montalban-Bravo, MD, Guillermo Garcia-Manero, MD, Nicholas J. Short, MD, Koji Sasaki, MD, Mikkael A. Sekeres, MD, MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Gail J. Roboz, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Courtney DiNardo, MD, Darla Miller, Zeev Estrov, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD and Elias Jabbour
   
   
7. 2888 -A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure (Poster)
   Aziz Nazha, MD, Rami S. Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, PhD, Katrina Zell, MA, MS, Cassie Zimmerman, MPH, Najla H. Al Ali, BDS, MSc, Gail J Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Eric Padron, MD, Elias J. Jabbour, MD, Molly Dara Greenberg, BS, Alan F. List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD, PhD and Mikkael A. Sekeres, MD, MS
   
   
8. 2889 - Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) (Poster)
   Amy E. DeZern, MD, MHS, Amer M. Zeidan, MBBS, MHS, John Barnard, PhD, Wesley Hand, Najla Al Ali, Francis Brown, Cassie Zimmerman, MPH, Gail J Roboz, MD, Rami S. Komrokji, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD and Mikkael A. Sekeres, MD, MS

Oral Presentations from 2015 Evans Fellows

1. 86 - The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML) (Oral Session)
   Aziz Nazha, MD, Ahmad Zarzour, MD, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD, MBA, Jennifer S. Carew, Ph.D., Cassandra M Hirsch, Kassy E Kneen, Bartlomiej Przychodzen, MSc, Bhumika J. Patel, Michael Clemente, MS, Srinivasa R. Sanikommu, MBBS, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD, Ph.D. and Mikkael A. Sekeres, MD, MS
   
   
2. 300 - Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia (Oral Session)
   Bhumika J. Patel, Bartlomiej Przychodzen, MSc, Michael J. Clemente, Cassandra M. Hirsch, Tomas Radivoyevitch, PhD, Swapna Thota, MD, Aziz Nazha, MD, Hetty E. Carraway, MD, MBA, Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, PhD
   
   
3. 607 - The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS) (Oral Session)  Aziz Nazha, MD, Mayur Subhash Narkhede, MD, Tomas Radivoyevitch, PhD, Matt Kalaycio, MD, Bhumika J. Patel, Aaron T. Gerds, MD, MS, Sudipto Mukherjee, MD, PhD, Michael Clemente, MS, Cassandra M Hirsch, Anjali S. Advani, MD, Bartlomiej Przychodzen, MSc, Hetty E. Carraway, MD, MBA, Jaroslaw P. Maciejewski, MD, Ph.D. and Mikkael A. Sekeres, MD, MS
   
   
4. 608 - The Complete Mutatome and Clonal Architecture of Del(5q) (Oral Session)
   Vera Ademà, MSc, Laura Palomo, MSc, Przychodzen P Bartlomiej, Diez-campelo Maria, MD, Naoko Hosono, MD, PhD, Mar Mallo, PhD, Blanca Xicoy, MD, PhD, Elisa Luño, Bhumika J. Patel, Cassandra M Hirsch, Lurdes Zamora, PhD, Thomas LaFramboise, PhD, Leonor Arenillas, MD, Albert Perez-Ladaga, PhD, Carme Pedro, Michael J. Clemente, Joan Bargay, MD, Julia Montoro, MD, Juan Carlos Caballero, MD, Brayan Merchan, MD, Victor Noriega, MD, Victor Marcos-Betes, MD, Consuelo Del Cañizo, MD, PhD, Rosario Lopez, PhD, José María Raya, MD, Joaquin Sanchez-Garcia, MD, Eduardo Rios, Montserrat Arnan, MD, PhD, Lourdes Florensa, MD, PhD, Raquel de Paz, Angelina Lemes, MD, Paula Gomez-Marzo, MSc, Nuri Haro, Francisco Fuster-Tormo, MSc, Monica Bayes, PhD, Ivo Gut, Rafael Bejar, MD, PhD, Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, Ph.D. and Francesc Sole, PhD
   
   
5. 611 - Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes (Oral Session)
   Aziz Nazha, MD, Bartlomiej Przychodzen, MSc, Hideki Makishima, MD, Ph.D., Hetty E. Carraway, MD, MBA, Bhumika J. Patel, Cassandra M Hirsch, Michael Clemente, MS, Srinivasa R. Sanikommu, MBBS, Aaron T. Gerds, MD, MS, Jennifer S. Carew, Ph.D., Satoru Miyano, MD, Ph.D., Matt Kalaycio, MD, Seishi Ogawa, MD, Ph.D., Jaroslaw P. Maciejewski, MD, Ph.D. and Mikkael A. Sekeres, MD, MS
   
   
6. 144 - Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype (Oral Session)
   Sheng Wei, MD, Erika Adriana Eksioglu, PhD, MS, Xianghong Chen, PhD, Thomas Cluzeau, MD, PhD, Ashley Basiorka, Alexis Burnette, Max Wei, Kathy L McGraw, Ph.D., Eric Padron, M.D. and Alan F. List, MD
   
   
7. 286 - Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition (Oral Session)
   Matthew S Beatty, PhD, Rebecca S Hesterberg, BA, Ying Han, MD, Eric Padron, M.D., Adam W Mailloux, PhD, Sean Yoder, M.S, Anjali M Rajadhyaksha, PhD, Alan F. List, MD and Pearlie K Epling-Burnette, PhD
   
   
8. 356 - Cooperating Effect of Rps14, Csnk1a1 and miRNA145/miRNA146a Haploinsufficiency in the Activation of the Innate Immune System in Del(5q) MDS (Oral Session)
   Schneider K. Rebekka, MD, Monica Schenone, PhD, Monica Ferreira Ventura, PhD, Fabian Beier, MD, Tim H. Bruemmendorf, MD, Ulrich Germing, MD, Uwe Platzbecker, MD, Guntram Büsche, MD, Marie E. McConkey, PhD, Christopher S Waters, R. Coleman Lindsley, MD, PhD and Benjamin L. Ebert, MD

Poster Presentations from 2015 Evans Fellows

1. 1319 - Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy (Poster)
   Ahmad Zarzour, MD, Aziz Nazha, MD, Matt Kalaycio, MD, Bhumika J. Patel, Aaron T. Gerds, MD, MS, Michael J. Clemente, Cassandra M Hirsch, Jennifer S. Carew, PhD, Anjali S. Advani, MD, Srinivasa R. Sanikommu, MBBS, Bartlomiej Przychodzen, MSc, Hetty E. Carraway, MD, MBA, Sudipto Mukherjee, MD, PhD, Jaroslaw P. Maciejewski, MD, Ph.D. and Mikkael A. Sekeres, MD, MS
   
   
2. 1645 - TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition (Poster)
   Aziz Nazha, MD, Manja Meggendorfer, PhD, Niroshan Nadarajah, M.Sc., Kassy E Kneen, Tomas Radivoyevitch, PhD, Bartlomiej Przychodzen, MSc, Hideki Makishima, MD, Ph.D., Bhumika J. Patel, Srinivasa R. Sanikommu, MBBS, Sean Hobson, Mridul Mukherji, PhD, Mikkael A. Sekeres, MD, MS, Torsten Haferlach and Jaroslaw P. Maciejewski, MD, Ph.D.
   
   
3. 1652 - Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA) (Poster)
   Eiju Negoro, MD, PhD, Naoko Hosono, MD, PhD., Wenyi Shen, MD, Tetsuichi Yoshizato, MD, Bhumika J. Patel, Cassandra Hirsh, BSc, Bartlomiej Przychodzen, MSc, Michael J. Clemente, Reda Z. Mahfouz, MD/PhD, Aleksandra Wodnar-Filipowicz, PhD, Hideki Makishima, MD, Ph.D., Seishi Ogawa, MD, Ph.D., Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, Ph.D.
   
   
4. 2848 - Determinants of Phenotypic Commitment and Clonal Progression-- Conclusions from the Study of Clonal Architecture in CMML (Poster)
   Bhumika J. Patel, Bartlomiej Przychodzen, MSc, Michael J. Clemente, Cassandra M. Hirsch, Tomas Radivoyevitch, PhD, Swapna Thota, MD, Thomas LaFramboise, PhD, Hirotoshi Sakaguchi, MD, PhD, Seiji Kojima, MD, PhD, Hetty E. Carraway, MD, MBA, Mikkael A. Sekeres, MD, MS, Seishi Ogawa, MD, Ph.D., Hideki Makishima, MD, Ph.D. and Jaroslaw P. Maciejewski, MD, Ph.D.
   
   
5. 771 - Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients: A Feasibility Pilot Study (Poster)
   Amy E. DeZern, MD, MHS, Katherine Williams, Karen E. King, MD, Wesley Hand, Mark J. Levis, MD, PhD, B Doug Smith, MD, Ivana Gojo, MD, Keith W. Pratz, MD, Lukasz P Gondek, MD, PhD, Gabrielle T. Prince, MD, Gabriel Ghiaur, MD, PhD, Margaret M. Showel, MD, Douglas Gladstone, MD, Steve Frank and Paul M. Ness, MD
   
   
6. 1673 - Prognostic Impact of ASXL1 Mutations in MDS and CMML (Poster)
   David Sallman, M.D., Eric Padron, M.D., Christine Vaupel, PhD, Thomas Cluzeau, MD, PhD, Najla H. Al Ali, BDS, MSc, Jeffrey E Lancet, MD, Jeff Hall, PhD, Alan F. List, MD and Rami S. Komrokji, MD
   
   
7. 4121 - P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes (Poster)
   Nguyen Johnny, MD, Kathy L McGraw, Ph.D., Rami S. Komrokji, MD, David Sallman, M.D., Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Jeffrey E Lancet, MD, Lynn C. Moscinski, M.D., Alan F. List, MD and Ling Zhang, MD
   
   
8. 4382 - TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (Poster)
   Mohamed A. Kharfan-Dabaja, M.D., Rami S. Komrokji, MD, Qing Zhang, PhD, David Sallman, M.D., Asmita Mishra, M.D., Najla H. Al Ali, BDS, MSc, Taiga Nishihori, M.D., Teresa Field, M.D., PhD, Karma Z Salem, M.D., Janelle Perkins, PharmD, Ling Zhang, M.D., Lynn C. Moscinski, M.D., Hugo F. Fernandez, M.D., Jeffrey E Lancet, M.D., Alan F. List, MD, Claudio Anasetti, M.D. and Eric Padron, M.D.
   
   
9. 1659 - NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders (Poster)  
   Syed A Mian, BSc, M.Phil, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPath, Aytug Kizilors, PhD, Kathy L McGraw, Ph.D., Shahram Kordasti, MD, PhD, Stephan Menzel, PhD, Alexander e Smith, PhD, Pilar Perezabellan, MSc, David Sallman, M.D., Alan F. List, MD and Ghulam J Mufti, FRCP, FRCPath
   
   
10. 1641 - Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML) (Poster)
    Maria E. Balasis, Jane Merelvede, Sateesh Kunigal, Xiaoyi Ren, Yan Ma, Qing Zhang, PhD, Jeff Painter, Nathalie M. Droin, PhD, Joseph Johnson, Sean Yoder, M.S, Rami S. Komrokji, MD, Ling Zhang, MD, Sheng Wei, MD, Torsten Haferlach, Robert MacLeod, PhD, Alan F. List, MD, Eric Solary, MD, Prof, P.K. Epling-Burnette, PhD and Eric Padron, MD
    
    
11. 1658 - Pacritinib (PAC) Synergistically Potentiates Azacitidine (5AZA) Cytotoxicity in Chronic Myelomonocytic Leukemia (CMML) (Poster)
    Yan Ma, MD, Lily Remsing Rix, Qing Zhang, MD, Maria E. Balasis, Rami S. Komrokji, MD, Uwe Rix, PhD, Alan F. List, MD and Eric Padron, MD
    
    
12. 1664 - Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS) (Poster)
    Rami S. Komrokji, MD, Mintallah Haider, MD, Najla H. Al Ali, BDS, MSc, Jeffrey E Lancet, M.D., Qing Zhang, MD, Pearlie K Epling-Burnette, PhD, Alan F. List, MD and Eric Padron, MD
    
    
13. 2112 - What Is the Impact on Quality of Life of Various Treatments in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome? Rethinking the Goals (Poster)
    Sara M. Tinsley, PhD, ARNP, AOCN, Brent J Small, PhD, Jeffrey E Lancet, M.D., Susan C McMillan, PhD, ARNP, Rami S. Komrokji, MD, Eric Padron, M.D., Kenneth S. Zuckerman, MD and Alan F. List, MD
    
    
14. 2897 - Eltrombopag Use in Chronic Myelomonocytic Leukemia (CMML) Patients: A Cautionary Tale (Poster)
    Hanadi Ramadan, BA, Vu H. Duong, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Ling Zhang, MD, Jeffrey E Lancet, MD, Alan F. List, MD and Rami S. Komrokji, MD
    
    
15. 2898 - Myelodysplastic Syndromes in Adolescent Young Adults (AYA) (Poster)
    Joanna (Asia) Grabska, MD, Bijal D. Shah, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, M.D., Hanadi Ramadan, BA, Jeffrey E Lancet, MD, Alan F. List, MD and Rami S. Komrokji, MD
    
    
16. 4076 - Refining Triage to Polycythaemia Vera or Primary Myelofibrosis Based on Targeted Molecular Profiling By Clinical Next Generation Sequencing (Poster)
    Song Jinming, M.D., Ph.D, Mohammad Omar Hussaini, MD, Haipeng Shao, M.D., Ph.D., Eric Padron, M.D., Jeffrey E Lancet, M.D., Rami S. Komrokji, MD, Ling Zhang, MD and Lynn C. Moscinski, M.D.
    
    
17. 1156 - Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate (Poster)
    Matteo Marchesini, PhD, Yamini Ogoti, Irene Ganan-Gomez, PhD, MSc, Yue Wei, PhD, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, MD, Ronald A. DePinho and Simona Colla, PhD
    
    
18. 2852 - Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse (Poster)  
    Irene Gañán-Gómez, PhD, Yamini Ogoti, Matteo Marchesini, PhD, Yue Wei, PhD, Hui Yang, MD, PhD, Shan Jiang, Naran Bao, Carlos E. Bueso-Ramos, MD, Guillermo Garcia-Manero,
    MD and Simona Colla, PhD
    
    
19. 1205 - A Novel Conditional Knockout of the Diamond Blackfan Anemia Gene Rpl11 Shows Failure of Erythropoiesis, a Marked Increase in BFU-E Progenitors By Phenotype That Proliferate Poorly in Culture, and Activation of p53 Target Genes (Poster)
    Cailin E Joyce, PhD, Meaghan McGuinness, BS, Rebekka K Schneider, MD, Mark D. Fleming, MD, DPhil, Dean R Campagna, BS, Paul J Schmidt, PhD, Benjamin L Ebert, MD, PhD, Carl D. Novina, MD, PhD and Colin A. Sieff, MB.BCh